Skip to main content
main-content
Top

23-06-2020 | Rheumatology | News | Article

Regulatory update

COVID-19: FDA revokes Emergency Use Authorization for hydroxychloroquine

Author:
Claire Barnard

medwireNews: The US FDA no longer permits the use of chloroquine or hydroxychloroquine for the treatment of COVID-19 outside of clinical trial settings.

The Emergency Use Authorization (EUA), which permitted the use of these agents to treat certain hospitalized COVID-19 patients when participation in a clinical trial was not possible, was revoked because “the legal criteria for issuing an EUA are no longer met,” announced the FDA in a news release.

Following “rigorous” assessment of emerging data, the agency said that“[t]he totality of scientific evidence currently available indicate a lack of benefit.”

Considered alongside the risks including serious cardiac events, “the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks” when used for the treatment of COVID-19, concluded the FDA.

Both agents are approved for the treatment of malaria, while hydroxychloroquine is also approved for systemic lupus erythematosus and rheumatoid arthritis.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

23 June 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits